Evogene Ltd. (EVGN) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Evogene Ltd. (EVGN) closed at USD 0.38 on 2026-10-14, a change of -71 % over the past year, with a market capitalization of USD 6.32M.
Evogene Ltd. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 0.38 |
| 2026-10-13 | 0.39 |
| 2026-10-12 | 0.39 |
| 2026-10-09 | 0.38 |
| 2026-10-08 | 0.40 |
| 2026-10-07 | 0.41 |
| 2026-10-06 | 0.42 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Evogene Ltd. key figures
- Previous close
- USD 0.38 (2026-10-14)
- 1-year change
- -71 %
- Market cap
- USD 6.32M
- Enterprise value
- USD 7.26M
- P/E ratio (trailing)
- -0.26
- P/E ratio (forward)
- -0.67
- EPS (trailing)
- -1.55
- EPS (forward)
- -0.60
- PEG ratio
- n/a
- Price to book
- -1.65
- Revenue growth
- -60.7 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.28
- Employees
- 38
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Evogene Ltd. and compare it with other stocks.
Analyze EVGNAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Evogene Ltd. shares.